CE

C&D Emerging Investment

Asia, Fujian, China, Xiamen

Description

C&D Emerging Investment specializing in minority equity investment.

Investor Profile

C&D Emerging Investment has made 5 investments, with 0 in the past 12 months and 20% as lead.

Stage Focus

  • Series C (40%)
  • Series D (20%)
  • Series E (20%)
  • Series B (20%)

Country Focus

  • China (100%)

Industry Focus

  • Health Care
  • Pharmaceutical
  • Biotechnology
  • Therapeutics
  • Medical
  • Product Research
  • B2b
  • Cosmetics
  • E-commerce
  • Logistics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does C&D Emerging Investment frequently co-invest with?

China Pacific Insurance
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Yuexiu Group
Asia, Hong Kong Island, Hong Kong, Wan Chai
Co-Investments: 1
Lake Bleu Capital
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 1
CCBT Private Equity
Asia, Beijing, China, Beijing
Co-Investments: 1
B
Asia, Beijing, China, Beijing
Co-Investments: 1
GC
Asia, Zhejiang, China, Huzhou
Co-Investments: 1
Dingxin Capital
Asia, Guangdong, China, Shenzhen
Co-Investments: 1
CS
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Exome Asset Management
North America, New York, United States, New York
Co-Investments: 1
Lilly Asia Ventures
Asia, Shanghai, China, Shanghai
Co-Investments: 1

Which angels does C&D Emerging Investment often collaborate with?

SI
North America, New York, United States, New York
Shared Deals: 1

What are some of recent deals done by C&D Emerging Investment?

Bang Er Orthopedic

Hangzhou, Zhejiang, China

Bang Er Orthopedic is a Hangzhou based healthcare company.

Health CareMedical
Series ENov 9, 2023
Amount Raised: $109,840,320
Oricell Therapeutics

Shanghai, Shanghai, China

OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy.

Health CarePharmaceuticalProduct Research
Series BFeb 28, 2023
Amount Raised: $45,000,000
IMPACT Therapeutics

Nanjing, Jiangsu, China

IMPACT Therapeutics is a therapeutics company dedicated to the development of similar drugs to treat cancer.

BiotechnologyPharmaceuticalTherapeutics
Series DMar 14, 2022
SiBionics

Shenzhen, Guangdong, China

SiBionics is a medtech company that engages in the field of chronic disease management.

Artificial Intelligence (AI)Health CareMedical Device
Series CJan 21, 2022
Amount Raised: $126,000,000
XINGYUN GROUP

Shenzhen, Guangdong, China

Xingyun Group comprehensive services platform for global commodities.

B2BCosmeticsE-CommerceLogisticsSaaSSupply Chain Management
Series CSep 24, 2020
Amount Raised: $200,000,000